References
- Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521–2536.
- Kumar SK, Rajkumar SV, Dispenzieri A, et al Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2120.
- Kristinsson SY, Landgren O, Dickman PW, et al Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993–1999.
- Ries LA, Melbert D, Krapcho M, et al SEER Cancer Statistics Review. 1975–2005. Available from: www. seer.cancer.gov
- Facon T, Mary JY, Pégourie B, et al Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292–1298.
- Hulin C, Facon T, Rodon P, et al Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664–3670.
- Palumbo A, Bringhen S, Caravita T, et al Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825–831.
- Offidani M, Corvatta L, Piersantelli MN, et al Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006;108:2159–2164.
- Durie BG, Harousseau JL, San Miguel JS, et al International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
- Phekoo KJ, Schey SA, Richards MA, et al A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004;127:299–304.
- Facon T, Mary JY, Hulin C, et al Melphalan and prednisone plus thalidomde versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma. Lancet 2007;370:1209–1218.
- Gulbrandsen N, Waage A, Gimsing P, et al A randomised placebo controlled study with melphalan/prednisone vs melphalan/prednisone/thalidomide: quality of life and toxicity. Haematologica 2008;93(Suppl. 1): Abstract 209.
- Wijermans P, Schaafsma M, Van Norden Y, et al Melphalan+prednisone vs melphalan+prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative GROUP HOVON. Haematologica 2008;93(Suppl. 1): Abstract 440.
- Hernandez JM, Garcia-Sanz R, Golvano E, et al Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004;127:159–164.
- Ludwig H, Hajek R, Tóthová E, et al Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113:3435–3442.
- Rajkumar SV, Blood E, Vesole D, et al Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–436.
- Rajkumar SV, Rosiñol L, Hussein M, et al Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171–2177.
- Rajkumar SV, Jacobus S, Callander NS, et al Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.
- Zangari M, Siegel E, Barlogie B, et al Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:1168–1171.
- Zangari M, Barlogie B, Anaissie E, et al Deep venous thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004;126:715–721.
- Bradley MA, Begum G, Barth NJ, et al Early mortality following diagnosis of multiple myeloma: analysis of patients entered into the UK Medical Reasearch Council Trials 1980–2002. Blood 2004;104(Suppl. 1):944a. (Abstract 3465)
- Ishak J, Dimopoulos MA, Weber D, et al Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. Blood 2008;112(Suppl. 1):1271. (Abstract 3708).